Second, measuring PD-L1 on CD14+ cells or neutrophils alone is insufficient to determine the effectiveness of anti-PD-(L)1 treatment, since other factors such as tumor mutations and immune cell infiltration may also play significant roles in predicting treatment response. Here, CD14 is linked to neoplasm.